Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Infliximab vs Cyclophosphamide in Severe Behçet's Disease
NCT03371095Phase 3Completed
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- May 2018
- Primary completion
- Dec 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of infliximab in Behçet's disease (BD), sponsored by Assistance publique - Hôpitaux de Paris. Started May 2018; status: completed.
02
Drugs
infliximab
03
Conditions
Behçet's disease (BD)
Beyond the preview
Go deeper on NCT03371095.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03371095.